UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant ⊠ Filed by a party other than the Registrant □		
Che	Check the appropriate box:	
	Preliminary Proxy Statement	
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))	
	Definitive Proxy Statement	
\times	Definitive Additional Materials	
	Soliciting Material under § 240.14a-12	
Unicycive Therapeutics, Inc.		
(Name of Registrant as Specified In Its Charter)		
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)		
Payment of Filing Fee (Check all boxes that apply):		
\boxtimes	No fee required	
	Fee paid previously with preliminary materials.	
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11	





UNICYCIVE THERAPEUTICS, INC.

2023 Annual Meeting Vote by June 25, 2023 11:59 PM ET



Ricky Campana P.O. Box 123456 Suite 500 51 Mercedes Way Edgewood, NY 11717

lidodadladladladladladladladladl





You invested in UNICYCIVE THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 26, 2023.

1 OF 322,224 148,294

30#

Get informed before you vote

View the Form 10-K, Notice & Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 12, 2023. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email



For complete information and to vote, visit www.ProxyVote.com

Control#





Smartphone users

Point your camera here and vote without entering a control number



Vote in Person at the Meeting*

June 26, 2023 9:00 AM PDT

4300 El Camino Real Suite 210 Los Altos, CA 94022

[&]quot;If you choose to vote these shares in person at the meeting, you must request a "legal proxy." To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

UNICYCIVE THERAPEUTICS, INC. 2023 Annual Meeting Vote by June 25, 2023 11:59 PM ET

Voting Items	
Election of Directors	
Nominees:	
Dr. Gaurav Aggarwal	⊘ For
Dr. Shalabh Gupta	For
Dr. Sandeep Laurnas	For
Dr. John Ryan	For
Proposal to ratify Mayer Hoffman McCann P.C. as the Companys independent registered public accountants for the fiscal year ending December 31,2023.	© For
Approval, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance by the Company of shares of common stock pursuant to the terms of the private placement financing transaction set forth in the Securities Purchase Agreement dated as of March 3, 2023 between the Company and each of the investors named therein, the Certificate of Designation of Preferences, Rights and Limitation of our Series A Convertible Voting Preferred Stock and the other documents and agreement related thereto, without giving effect to the caps on issuing shares contained therein.	⊘ For
Approval of an amendment to the Company's amended and restated certificate of incorporation to effect a reverse stock split of the Company's outstanding common stock, at a ratio within the range of 1-for-2 to 1-for-20, with the final ratio to be selected by our board of directors in its discretion at any time, if at all, within one year of the date of the Annual Meeting without further approval or authorization of our stockholders.	⊘ For
Approval of the amendment and restatement of the 2021 Omnibus Equity Incentive Plan.	For
E: Such other business as may properly come before the meeting or any adjournment thereof.	
	Election of Directors Nominees: Dr. Gaurav Aggarwal Dr. Shalabh Gupta Dr. Sandeep Laurnas Dr. John Ryan Proposal to ratify Mayer Hoffman McCann P.C. as the Companys independent registered public accountants for the fiscal year ending December 31,2023. Approval, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance by the Company of shares of common stock pursuant to the terms of the private placement financing transaction set forth in the Securities Purchase Agreement dated as of March 3, 2023 between the Company and each of the investors named therein, the Certificate of Designation of Preferences, Rights and Limitation of our Series A Convertible Voting Preferred Stock and the other documents and agreement related thereto, without giving effect to the caps on issuing shares contained therein. Approval of an amendment to the Company's amended and restated certificate of incorporation to effect a reverse stock split of the Company's outstanding common stock, at a ratio within the range of 1-for-2 to 1-for-20, with the final ratio to be selected by our board of directors in its discretion at any time, if at all, within one year of the date of the Annual Meeting without further approval or authorization of our stockholders.

Under New York Stock Exchange rules, brokers may vote "routine" matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting. We will nevertheless follow your instructions, even if the broker's discretionary vote has already been given, provided your instructions are received prior to the meeting date.

1.0000 322,22 148,29